Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Cardinal Health Has Acquired Six China Drug Distributors for $120 Million

publication date: Feb 6, 2013
Cardinal Health, a major US drug distributor, says it has spent $120 million to acquire six China drug distributors during the last year, paying less than $30 million for each one.  Cardinal’s CFO Jeff Henderson said the goal with each transaction was not revenue volume but greater geographical reach. The acquisition targets were not named. In 2010, Cardinal made a dramatic entry in China’s drug distribution sector by purchasing Zuellig China for $458 million. More details....

Stock Symbol: (NYSE: CAH)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital